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Abstract
Background: Dozens of Traditional Chinese Medicine (TCM) formulas have been used for promotion of “blood
production” for centuries, and we are interested in developing novel thrombopoietic medicines from these TCMs.
Our previous studies have demonstrated the hematopoietic effects of DangGui BuXue Tong (DBT), a formula
composed of Radix Angelicae Sinensis and Radix Astragali in animal and cellular models. As a step further to identify
and characterize the active chemical components of DBT, we tested the hematopoietic and particularly,
thrombopoietic effects of polysaccharide-enriched fractions from the root of Radix Angelicae Sinensis (APS) in this
study.
Methods: A myelosuppression mouse model was treated with APS (10 mg/kg/day). Peripheral blood cells from
APS, thrombopoietin and vehicle-treated samples were then counted at different time-points. Using the colony-
forming unit (CFU) assays, we determined the effects of APS on the proliferation and differentiation of
hematopoietic stem/progenitor cells and megakaryocytic lineages. Using a megakaryocytic cell line M-07e as
model, we analyzed the cellular apoptosis progression with and without APS treatment by Annexin V,
Mitochondrial Membrane Potential and Caspase 3 assays. Last, the anti-apoptotic effect of APS on cells treated with
Ly294002, a Phosphatidylinositol 3-Kinse inhibitor (PI3K) was also tested.
Results: In animal models, APS significantly enhanced not only the recovery of platelets, other blood cells and
their progenitor cells, but also the formation of Colony Forming Unit (CFU). In M-07e cells, we observed the anti-
apoptotic effect of APS. Treatment by Ly294002 alone increased the percentage of cells undergoing apoptosis.
However, addition of APS to Ly294002-treated cells significantly reduced the percentage of cells undergoing
apoptosis.
Conclusions: APS promotes hematopoiesis and thrombopoiesis in the mouse model. This effect likely resulted
from the anti-apoptosis activity of APS and is likely to involve the PI3K/AKT pathway.
Background
Thrombocytopenia (an abnormal decrease in the number
of platelets in circulatory blood) is frequently developed
in hematological and cancer patients who undergo bone
marrow suppression or infiltration resulting from che-
motherapy or radiotherapy. This condition may lead to
haemorrhage and fatality [1]. In severe cases, platelet
transfusion may be required to prevent or stop bleeding.
However, platelet transfusion may induce the formation
of anti-platelet antibodies, and the transmission of both
viral and bacterial infection. Until today, no effective
treatments for thrombocytopenia are clinically available.
Our long term goal is to identify novel thrombopoietic
agents from Traditional Chinese Medicine (TCM)
formulations or products for further development.
Dozens of TCM formulations have been used for pro-
motion of “blood production” for centuries and have
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Previously, we specifically characterized Danggui Buxue
Tong (DBT) and demonstrated that it has significant
effects on promoting thrombopoiesis [4]. Many chemical
components have been identified in DBT. Among them
is the polysaccharide fraction of Angelica sinensis (APS).
The structure of the APS-iron complex (APIC) had
been proposed to be a polynuclear ferrihydrite core che-
lated firmly by an encircling framework of APS chains,
forming a core molecule, which is surrounded by a
removable outer protective sheath of colloidal APS. The
molecular formula of APIC was proposed to be
{[(Fe2O3·2.2H2O)1043(APS)32](APS)12}, with MW =
270000 Da [5]. Recent pharmacological studies demon-
s t r a t e dt h a tA P Sh a dr a d i o - p rotective effects in irra-
diated mice through modulation of proliferating
response of hematopoietic stem cells [2]. In gastrointest-
inal system, APS was known to be protective against
ethanol- or indomethacin-induced mucosal damage [6].
It was also reported that Angelica sinensis crude extract
increased the proliferation of gastric epithelial cells
through modulation of several proliferation-related
genes, including EGF, ODC, and c-Myc [7-9]. In cancer
cells, APS has been reported to possess anti-tumor
effects [10,11].
Although several studies have demonstrated the gen-
eral hematopoietic activity of APS, no study has been
performed to specifically determine its thrombopoietic
effects. In addition, the mechanism of action of APS’s
effect has not been investigated. Here, we tested if APS
can promote thrombopoiesis. Firstly, we confirmed that
APS can promote the recovery of various hematopoietic
lineages in a mouse model. Secondly, we found that
APS can promote the proliferation of megakaryocytic
progenitor cells and bone marrow stromal cells in vitro,
which might directly lead to the platelet production.
Thirdly, APS can also inhibit the apoptosis of megakar-
yocytic cells in vitro. In separate studies, our lab has
found that Phosphatidylinositol 3-kinase/AKT is likely
to be involved in the APS’se f f e c t s .A sar e s u l t ,aP I 3
kinase inhibitor was used to treat the cells with or with-
out APS. We found that APS reversed the effects of
Ly294002, a PI3 kinase inhibitor. In summary, the cur-
rent study has demonstrated the promoting effect of
APS on thrombopoiesis and this effect might involve the
PI3K/AKT pathways. The work from this study laid the
foundation for the development of possible APS based
therapeutic strategies.
Methods
Plant Materials and Chemical Reagents
The roots of Angelica sinensis (Oliv.) Diels, (RAS, Chi-
nese name: Danggui) used in our experiments were pur-
chased from Minxian County, Gansu Province, China.
These samples are currently deposited in the Molecular
Chinese Medicine Laboratory, University of Hong Kong
as voucher # mcm-011. The standard RAS materials
used for quality control was purchased from National
Institute for the Control of Pharmaceutical and Biologi-
cal Products, China (batch number: 120927-200411).
Anthrone and glucose were purchased from Guoyao
Enterprise group, Tianjing Damao Chemicals Company
(Tianjing, China). Sulfuric acid was purchased from
Sigma-Aldrich (St Louis, MO).
Quantitative Analysis of Plant Materials
The experimental and standard RAS materials were
dried at 60°C, ground and powdered by an electric mill
( T R - 0 2 B ,R o n gT s o n g ,T a i w a n )a n ds i e v e dt h r o u g ha
mesh (size 20). The powders were then ground with
KBr (AR, Perkin Elmer, UK) and pressed into pellets
using a KBr hand press (Specac, UK). The pellets were
analyzed by a Spectrum 100 (PerkinElmer, UK) under
the following conditions, wavelength range: 400 to 4000
cm
-1; spectral resolution: 4 cm
-1. Data analysis was per-
formed using software PerkinElmer Spectrum (Version
6.2.0).
Preparation and Quantitative Analysis of APS Samples
RAS polysaccharides (APS) were prepared according to
the method described by Cho et al [6]. Briefly, 100
grams of RAS were extracted three times by boiling in
water for four-hours each time. All water extracts were
pooled and mixed with ethanol to a final concentration
of 75% v/v to precipitate the polysaccharide-enriched
fraction (APS). The total amounts of polysaccharides
were measured using the anthrone-sulfuric acid assay.
Briefly, the standard glucose solution was prepared in
MiliQ water at serial concentrations of 0, 0.010, 0.020,
0.040, 0.060 and 0.080 mg/ml. Four ml of anthrone-sul-
furic acid solutions (0.2 g/ml) were added to a 1 ml APS
solution and each of the six standard solutions respec-
tively. All solutions were kept and mixed on ice. The
mixtures were boiled in a water bath for 15 min and left
at room temperature for 10 min before they were ana-
lyzed using a UV/VIS Spectra Lambda 35 (PerkinElmer).
Three replicate analyses were conducted.
Testing Endotoxic Activity by Gel-clot Tachypleus
Amebocyte Lysate (TAL) Test
All materials required for TAL test including Tachy-
pleus Amebocyte Lysate, control standard endotoxin (10
EU/ml), TAL reagent water, test tubes and pipette tips
free of detectable endotoxin were purchased from Zhan-
jiang Bokang Marine Biological Co., LTD (Guangdong,
P.R.China). The gel-clot TAL tests were preformed
according to the method described in Chinese Pharma-
copoeia 2010 edition. Briefly, 100 μl series dilutions of
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with 100 μl TAL reagents. The mixed solutions were
incubated at 37°C for 60 minutes. The formation of the
gel was scored by turning each test tube upside down. If
the gel remained a piece, it is considered a solid gel for-
mation. Otherwise, it is considered a failed gel forma-
tion. Endotoxin is measured in Endotoxin Units per
milliliter (EU/ml). One EU equals approximately 0.4 ng/
ml of endotoxin solution in our experiment.
Radiation-induced Haematocytopenic Model
Seven to eight week-old male Balb/c mice were obtained
from Charles River Japan (Yokohama, Japan) and given
free access to food and water. The treatment of animals
were conducted following protocols provided by Hong
Kong government and ethical permissions for the stu-
dies were granted by the Animal Research Welfare
Committee, The Chinese University of Hong Kong. A
haematocytopenia with thrombocytopenia model was
established using 4-Gy-irradiated mice as described pre-
viously [12,13]. APS (2.5 mg/day) and TPO (0.25 μg/
day) were given by injection (IP) daily for 21 days start-
ing from the day after radiotherapy in these mice. Per-
ipheral blood platelets, white blood cells (WBC) and red
blood cells (RBC) from APS, TPO and water control
groups were analyzed on days 0, 7, 14, and 21. On day
21, the bone marrow cells were harvested for colony-
forming unit (CFU) assays. We measured the plasma
TPO levels on day 21. Bone marrow samples were fro-
zen in cryomolds and performed on 5-μm sections. The
slides were stained with Giemsa staining. Twenty-five
random high-power fields from each bone marrow sam-
ple were chosen and blindly quantified for histological
examination.
Murine Colony-Forming Unit (CFU) Assay
The assay was performed as described previously [14].
Colony-forming unit-granulocyte macrophage (CFU-
GM), burst-forming unit/colony-forming unit-erythroid
(BFU/CFU-E), and colony-forming unit-mixed (CFU-
GEMM) were cultured in methylcellulose (1%) supple-
mented with fetal calf serum (FCS, 30%), 1% BSA,
0.1 mM b-mercaptoethanol, 3 IU/ml erythropoietin,
10 ng/ml granulocyte macrophage-colony stimulating fac-
tor, 10 ng/ml interleukin-3, and 50 ng/ml SCF. Murine
bone marrow cells (2 × 10
5 cells/ml) were seeded in tripli-
cate and incubated for 7 days. Colonies were scored blindly.
Murine Colony-Forming Unit-Megakaryocytes (CFU-MK)
Assay
Murine bone marrow cells (2 × 10
5 cells) were cultured
using the plasma clot culture method [14,15]. The cul-
ture medium contains 1% deionized bovine serum albu-
min (BSA) (Sigma, Mo USA), 0.34 mg CaCl2, 10%
citrated bovine plasma (Sigma), 100 μg penicillin, 50 μg
streptomycin and IMDM with different concentrations
of APS, TPO and IL-3 in a total volume of 1 ml. The
cells were incubated at 37°C under 5% CO2 for 7 days
and the number of CFU-MK derived colonies was
counted using acetyl-choline esterase (AchE) staining
method after 7 days. The colonies were further stained
with haematoxylin to countt h eC F U - G Md e r i v e dc o l o -
nies. A CFU-MK colony was defined as a cluster of 3 or
more AchE positive cells and a CFU-GM colony was
considered as a cluster of 40 or more cells.
Murine Bone Marrow Colony-Forming Unit-Fibroblast
(CFU-F) assay
The assay was performed as described previously
[16,17]. Briefly, mouse bone marrow cells (1 × 10
6 cells)
were seeded in 2 ml of IMDM with 10% FCS in tripli-
cates. Cultured cells were incubated at 37°C and 5%
CO2 in a fully humidified atmosphere with or without
APS for 9 days. Fibroblastoid colony-forming cells
(CFU-F) assay were used to determine the number of
bone marrow-derived fibroblastoid [16]. Briefly, adher-
ent cells were stained with Giemsa staining. The num-
ber of CFU-F colonies was counted under a light
microscope. An aggregate containing more than 10
fibroblasts were counted as a CFU-F colony. Effects of
APS and other cytokines such as fibroblast growth fac-
tor (FGF, 50 ng/ml), platelet-derived growth factor
(PDGF, 50 ng/ml), or vascular endothelial growth factor
(VEGF, 50 ng/ml) were also examined using the CFU-F
assay.
Annexin V, Caspase 3, and Mitochondrial Membrane
Potential Analyses of M-07e Cells by Flow Cytometry
The assays were performed as described previously [14].
Briefly, the megakaryoblastic cell line M-07e (American
Type Culture Collection, Manassas, VA, http://www.
atcc.org) was maintained in IMDM supplemented with
GM-CSF (20 ng/ml) and 10% FCS. Apoptotic cell death
was induced by cytokine and serum depletion. We
added APS (200 μg/ml) to the cultures and then the
cells were incubated for 72 hours. Apoptotic cell death
was examined using the annexin V-FITC/PI, active Cas-
pase 3-PE, and JC-1 ApoAlert reagent kits (BD Bios-
ciences, San Diego, http://www.bdbiosciences.com)
according to the manufacturer’s instructions. Ten thou-
sand events were acquired for each sample and analyzed
by flow cytometry using the Lysis II software (FACScan;
BD Pharmingen).
Statistical Analysis
Treatment groups were compared using analysis of var-
iance, paired t test or Wilcoxon signed rank test,
depending on data distribution, using the JMP software
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statistically significant. All values were expressed as
mean ± SEM. Statistical significances were denoted with
three different symbols: “*” (p< 0.05), “#” (p< 0.01) and
“+” (p< 0.001).
Results
The current experimental studies include three parts: (1)
quality control of APS; (2) effects of APS on mice; (3)
effects of APS on the apoptosis of cells. In part 2, mice
(Normal) were subjected to radiotherapy to create a
bone-marrow-damaged model (Control). Then we study
the effects of APS on the recovery of various hemato-
poietic, especially those thrombopoietic cells. All treat-
ments were conducted on these control mice. In part 3,
apoptosis were induced in cells by serum depletion. The
effects of APS were tested on these apoptotic cells. In
our experiments, TPO was used as the positive control.
And a PI3K inhibitor was used to test if APS’s effects
implicate the PI3K pathway.
(1) Quality control of APS
Since the APS preparations usually contain various che-
mical compositions, qualitative and quantitative defining
the experimental materials is important. This is to
ensure that various preparations of RAS have consistent
biological activities and any follow-up studies can repro-
duce the results generated in previous studies. Here, we
used two methods to define our APS preparations. First,
the RAS samples were subjected to UV spectral analysis
and the spectrum were compared to that of a standard.
The IR spectrums of our RAS experimental material
and the RAS standard material are shown in Figure 1.
The above analyses were repeated five times and the
correlation coefficients of the spectrums were found to
be greater than 0.9973 (data not shown). Then we mea-
sured the total amounts of polysaccharides in the APS
preparations using the anthrone-sulfuric acid assay. Glu-
cose was used as the standard and the standard curve
was found to be y = 0.0069 * x + 0.0045 with a correla-
tion coefficient (R2) of 0.9992. By comparing to the
standard curve, polysaccharides were found to represent
90% of the total APS preparations.
Both bacterial endotoxins or lipopolysaccharide (LPS)
and (1,3)-b-D-glucan can trigger TAL gelation, which is
used for the detection and semi-quantification of the
LPS or b-glucan content of the APS preparation. We
found that the solid gel was formed for APS dilutions at
concentrations of 5, 1.667, 0.556, and 0.185 mg/ml. In
comparison, gelation occurred at concentrations of
0.125 and 0.06 EU/ml for the control standard endo-
toxin. So the LPS or b-glucan content of the APS pre-
paration was estimated to be approximately 0.06/0.185
or 0.32 EU/mg of APS extracts. This is equivalent to
0.128 ng endotoxin in 1 mg of APS.
(2) The effects of APS on hematopoiesis and
thrombopoiesis in myelosuppressed mice
Effects of APS on blood cell counts
As shown in Figure 2A, RBC counts of APS treated mice
showed significant increased recovery on days 7, 14
and 21. Similarly, RBC counts in TPO treated mice also
showed significant increased recovery on days 7, 14
and 21, suggesting that APS and TPO have similar effects
on the recovery of RBC cells. The changes of WBC cell
counts in the experiment were shown in Figure 2B. WBC
counts in APS treated mice showed significantly
increased recovery on days 7, 14 and 21. Similarly, WBC
counts in TPO treated mice also showed significantly
increased recovery on day 7, 14 and 21, suggesting that
APS and TPO have similar effects. Mice treated with
APS at 10 mg/kg/day showed significantly higher platelet
number on days 14 and 21 (Figure 2C) and accelerated
the platelet recovery compared with that of the control
mice. Similarly, TPO-treatment at 1 μg/kg/day signifi-
cantly increased the platelet counts comparing to that of
control on day 14 and 21. This thrombocytopoietic activ-
ity of APS was similar to that of TPO as there were no
significant differences in the platelet counts between
samples treated with APS and TPO.
Effects of APS on the total body weight and organ weight
Animal body weights in vehicle-, APS- and TPO-treated
groups were determined on days 0, 7, 14 and 21, respec-
tively. It showed a gradually increase on days 14 and 21
 
Figure 1 Spectrums of a RAS sample and the RAS standard.
The wavelengths are shown on the x axis and the values of
absorbance are shown on the Y axis. The wavelengths for the
identified peaks are indicated.
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in vehicle- and TPO-treated animals on day 7 after irra-
diated treatment, but this decrease was not observed in
APS treated mice (Figure 3A). It is possible that APS
protects the loss of body weight resulted from irradia-
tion. The body weights for mice treated with APS on
days 14 and 21 were significantly smaller than those in the
control group. Similarly, TPO treated mice showed signifi-
cantly smaller body weight on days 14 (p< 0.001) and 21
(p< 0.001). In the comparison of organ size (Figure 3B),
spleens in the APS-treated mice were significantly larger
 
Figure 2 Effects of APS on blood cell counts of irradiated mice
model. Mice (n = 6) were irradiated on day 0 and then treated
with vehicle (Control), APS (10 mg/kg/day, APS) and TPO (1 ug/kg/
day, TPO). The blood was taken and the numbers of (A). red blood
cells (RBC), (B). white blood cells (WBC) and (C). platelets were
counted. The statistical tests were carried out on the cell counts
between the corresponding tests and the control groups. *: p< 0.05;
#: p< 0.01 and +: p< 0.001.
Figure 3 Effects of APS on the animal body size and organ
size. Mice (n = 6) were irradiated on day 0 and then were treated
with vehicle (Control), APS (50 mg/kg/day, APS) and TPO (5 ug/kg/
day, TPO) as described in Figure 2. Their body weight and organ
size were then measured. Effects of APS and TPO treatments on the
animal weight (A), organ size (B) and organ size normalized by
body weight (C) are shown. The statistical tests were carried out on
the measurements of samples treated with APS and TPO and those
in the control group. For samples in the control group (A), the
comparisons were carried out between those of days 0, 14 and 21
and those of day 7. *: p< 0.05; #: p< 0.01 and +: p< 0.001.
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(p< 0.001). To determine the net effects of APS on the
animal organ size, we normalized the weight of the organ
to that of the body (Figure 3C). As shown, both liver
(p< 0.001) and spleen (p< 0.001) from the APS-treated
mice were significantly larger than those of the control
group and the TPO treated group. The mechanisms
underlying this observation remain to be elucidated.
APS significantly increased the formation of bone marrow
CFU
We then tested the in vivo effect of APS on the forma-
tion of hematopoietic CFU of the myeloid (CFU-GM),
erythroid (BFU/CFU-E), mixed (CFU-GEMM) and
megakaryocytic (CFU-MK) lineages, and bone marrow
stromal cells (CFU-F). Bone marrow cells in control,
APS and TPO treated animals were collected and cul-
tured for CFU assays. A pilot study has been conducted
to demonstrate the dose-dependent effects of APS on
bone marrow cells’ productions and also to determine
the optimal dose to be used in the following studies
(data not shown). As shown in Figure 4 treatment with
APS led to significant increase of the formation of CFU-
GM, BFU-E, CFU-GEMM, CFU-MK and CFU-F. The
different cell lineages, treatment groups and the corre-
sponding mean CFU counts are shown in Table 1.
Treatments that do not show significantly different
effects are grouped into the same treatment groups,
which are indicated by A, B, C or D respectively. As
shown in Table 1 APS and TPO significantly increase
the CFU counts in all cell lineages comparing to that of
the control. However, APS and TPO showed similar
effects for CFU-GM, CFU-GEMM and CFU-MK. For
BFU-E, TPO has a much stronger effect than APS, but
the effect is not strong enough to increase the CFU
counts to that of the normal samples. In contrast, for
CFU-F, APS has a very strong stimulating effect and it
i n c r e a s e dt h eC F U - Fc o u n t st ot h el e v e lo ft h en o r m a l
samples (Figure 4 and Table 1).
Effects of APS on bone marrow histology
We also investigated the bone marrow morphology
using Wright-Giemsa staining. Twenty-five randomly
selected areas of standardized size were examined
(4000×) for mean total cell counts (MTC) and mean
cell counts in the three cell lineages, erythroid, granu-
locytic and megakaryocytic series in each area. In the
irradiated mice (control, Figure 5B), the hematopoiesis
was markedly suppressed as evident from the dramatic
drop (~50%) in the MTC/area concomitant with an
increase of necrotic and apoptotic cells comparing to
the normal group (Figure 5A). The reduction was par-
ticularly prominent in the granulocytic (~60%) and
 
Figure 4 Effects of APS on the formation of CFU of the
myeloid (CFU-GM), erythroid (BFU-E), mixed (CFU-GEMM),
megakaryocytic (CFU-MK) and bone marrow stromal (CFU-F)
cells. The colony counts for various CFU with or without APS
treatment are shown. The statistical tests were carried out between
colony counts of APS, TPO treated samples and those of control
samples. Abbreviations: APS, Angelica Sinensis Polysaccharide; BFU/CFU-
E, burst-forming unit/colony-forming unit-erythroid; CFU, colony-
forming unit; CFU-E, colony-forming unit-erythroid; CFU-F, colony-
forming unit-fibroblast; CFU-GM, colony-forming unit-granulocyte
macrophage; CFU-GEMM: colony-forming unit-mixed; CFU-MK, colony-
forming unit-megakaryocyte. #: p< 0.01 and +: p< 0.001.
Table 1 Effect of APS on the formation of colony-forming
units (CFU)
Assays Treatment Group Mean
CFU Counts
Treatment Effect
Group
CFU-GM N 79.3 A
APS 52.3 B
TPO 50.0 B
C 34.5 C
BFU-E N 55.3 A
TPO 31.2 B
APS 22.3 C
C 8.3 D
CFU-GEMM N 27.7 A
APS 19.7 B
TPO 18.0 B
C 8.3 C
CFU-MK N 51.8 A
APS 32.5 B
TPO 37.5 B
C 15.3 C
CFU-F N 29.8 A
APS 27.6 A
TPO 19.3 B
C 8.8 C
The following CFUs, myeloid (CFU-GM), erythroid (BFU-E), mixed (CFU-GEMM),
megakaryocytic (CFU-MK) and bone marrow stromal (CFU-F) have been tested
for the effects of APS or TPO treatment. A, B, C and D indicates treatment
groups that have significantly different treatment effects. N: Normal, cells
cultured in the presence of cytokine and serum; C: Control, cells grown in
cytokine serum-depleted media; APS: Angelica Sinensis Polysaccharide; TPO:
Thrombopoietin.
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erythroid series. In the APS treated irradiated mice,
the bone marrow was hyperplastic (~ 70% increase of
cellularity) comparing to the normal, which was mainly
due to a prominent granulocytic expansion (Figure
5C). The megakaryocyte number was also significantly
increased than that of the control, being very close to
that of normal. In the TPO treated irradiated mice, tri-
lineage hematopoiesis was preserved although the
overall cellularity (MTC/area) was still slightly subnor-
mal, ~20% reduction could be observed compared to
normal (Figure 5D). The numbers of granulocytic and
megakaryocytic cells were very close to that of the nor-
mal group, indicating a better recovery of these cells
than the erythroid series, which showed essentially the
same number as the control. In conclusion, in both
the TPO and APS treated groups, there was signifi-
cantly increased recovery of the megakaryocytic and
granulocytic series by day 21 over the control group.
(3) APS Exerted Antiapoptotic Effects on M-07e Cells
As shown above, APS and TPO both promoted the
growth of RBCs, WBCs and platelets (Figure 2), and
their corresponding progenitor cells CFU-MK, CFU-GM
and BFU-E (Figure 4). Our previous studies suggest that
the increase of the cell population might also result
from the antiapoptotic effect of the agents in addition to
the direct stimulatory effect on cell growth [14]. Conse-
quently, we tested the antiapoptotic effect of APS using
megakaryocytic cell line M-07e.
We first detected the apoptosis of cells under various
treatments using the Annexin V assay (Figure 6). Annexin
V protein, which is conjugated to a fluorescent dye FITC,
is used to detect early and late apoptotic cells because it
specifically binds Phosphatidylserine (PS), which is translo-
cated from the inner leaflet of the plasma membrane to
the outer leaflet soon after the induction of apoptosis.
Another fluorescent dye Propidium Iodide (PI) is used to
stain the DNA in late apoptotic and necrotic cells whose
Figure 5 Effects of APS on bone marrow histology. The Wright-Giemsa stained bone marrow sections were examined for Normal (A), Control
(B), APS treated (C) and TPO treated (D) mice.
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are grouped based on the percentages of early (R2,
FITC+ and PI-), late (R1, FITC+ and PI+) and total
(R1+R2, FITC+) apoptotic cells (Table 2). As shown,
the lowest percentage of apoptotic cells were seen in
the normal samples and the highest percentage of
apoptotic cells were seen in the Ly294002 treated sam-
ples, while intermediate percentages of apoptotic cells
were seen in the control samples. Treatments with
APS and TPO significantly reduced the early (R2), late
(R1) and total (R1+R2) apoptotic cells comparing to
those of the control and their effects are not signifi-
cantly different. Comparing to treatment with
Ly294002 alone, additional APS treatment reduced the
percentages of apoptotic cells from 25.75% to 17.76%
for late apoptotic cells (R1) and from 41.88% to
32.25% in total apoptotic (R1+R2) cells. Interestingly,
no differences in percentages of early apoptotic cells
were observed among the Ly294002-treated (16.13%),
Control (15.71%) and APS+L-treated (14.49%) samples,
suggesting that APS might function mainly in prevent-
ing cells from proceeding to the late apoptotic phase.
Then, we confirmed the anti-apoptosis effects of APS
by JC-1 assay. JC-1 is one type of compound that aggre-
gate in mitochondria in normal cells (Figure 7A, red
fluorescence, detected in FL2) giving off red fluores-
cence. In apoptotic cells, the mitochondria transmem-
brane potential (m) breaks down, causing JC-1 to
remain in the cytoplasm in its monomer form and
fluorescing green (Figure 7A, green fluorescence,
detected in FL1). We measured the apoptotic cell
Figure 6 Effects of APS on apoptosis analyzed by annexin V
assay. Apoptosis was induced by serum depletion (control). APS,
TPO or Ly294002 were used to treat the cells for 72 hours. The cells
were stained with annexin V-FITC and Propidium Iodide (PI) and
subjected to flow cytometry analyses. (A). Dot plots of Normal, APS-
treated, Control, Ly294002-treated, TPO-treated, and APS+Ly294002-
treated samples. (B). Quantification and statistical analyses of
treatment effects. Percentages of R1 (FITC+, PI+, late apoptotic cells),
R2 (FITC+, PI-, early apoptotic cells) and R1+R2 (FITC+, total
apoptotic cells) are shown. Statistical tests were carried out between
the control/treated samples and the corresponding normal samples
respectively. *: p< 0.05; #: p< 0.01 and +: p< 0.001.
Table 2 Effects of various treatments on the apoptosis of
M-07e cells detected by annexin V assay
Treatment Group Percentage of Cells (%) Treatment
Effect Group
R1 L 25.75 A
APS + L 17.76 B
C 17.75 B
TPO 9.87 C
APS 9.21 C
N 3.86 D
R2 L 16.13 A
C 15.71 A
APS +L 14.49 A
APS 9.65 B
TPO 9.60 B
N 6.19 B
R1+R2 L 41.88 A
C 33.47 B
APS + L 32.25 B
TPO 19.47 C
APS 18.87 C
N 10.05 D
A, B, C and D stand for treatment groups having significantly different
treatment effects. R1: late apoptotic cells; R2: early apoptotic cells; R1+R2:
total apoptotic cells; N: Normal, cells cultured in the presence of cytokine and
serum; C: Control, cells grown in cytokine and serum-depleted media; APS:
Angelica Sinensis Polysaccharide; TPO: Thrombopoietin. L: Ly294002.
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gate and monomer forms (Figure 7 and Table 3). R1
represents cells contain both JC1 aggregates and mono-
mers, which are early apoptotic cells. R2 represents cells
contain only JC1 monomers, which are late apoptotic
cells. R1+R2 thus represent all apoptotic cells (Figure
7A). Compared with normal M-07e cells, cells from
control, Ly294002-treated, APS+Ly294002-treated
samples had significantly increased proportions of
cells containing JC-1 monomers (Figure 7B and Table
3), indicating the induction of apoptosis in these sam-
ples comparing to normal samples. Interestingly, no
significant differences were observed between apopto-
tic cells in APS or TPO treated samples comparing to
normal samples, indicating the protective effects of
APS and TPO treatments.
Last, we analyzed the anti-apoptosis effects of APS
using the Caspase 3 assay. Caspase 3 is a downstream
effector protein of apoptosis, expression of which is
indicative of undergoing apoptosis. M-07e cells were
treated as described, labelled with Caspase 3-PE dye
and then subjected to flow cytometry analysis. Histo-
grams of samples under various treatments are shown
in Figure 8A. Statistical testing between the indicated
samples and the normal samples are shown in Figure
8B. More detailed statistical testing results are summar-
i z e di nT a b l e4i nt h es a m em a n n e ra st h o s ef o r
Annexin V assay and JC-1 assay. As shown in Figure 8B
and Table 4 percentages of cells expressing Caspase 3
in APS-treated, TPO-treated samples are similar to
those of the normal. Ly294002-treated and the control
Figure 7 E f f e c t so fA P So na p o p t o s i sa n a l y z e db yJ C 1a s s a y .
M-07e cells were treated as described above, incubated with JC-1
reagent and then subjected to flow cytometry analyses. (A). Dot
plots of Normal, APS-treated, Control, Ly294002-treated, TPO-treated,
and APS+Ly294002-treated samples. (B). Quantification and statistical
analyses of treatment effects. Percentages of R1 (transitional cell
subset containing both JC1 aggregates and monomers,
representing early apoptotic cells), R2 (apoptotic cells containing
mostly monomers, representing late apoptotic cells), R1+R2 (total
apoptotic cells) cells are shown. Statistical tests were carried out
between the control/treated samples and the corresponding normal
samples respectively.*: p< 0.05; #: p< 0.01 and +: p< 0.001.
Table 3 Effects of various treatments on the apoptosis of
M-07e cells detected by JC1 assay
Treatment
Group
Percentage
of Total Cell
Population (%)
Treatment
Effect Group
R1 C 11.08 A
TPO 8.10 A B
L 8.04 A B
APS + L 7.83 A B
APS 7.61 A B
N 5.75 B
R2 C 33.84 A
L 28.01 A
APS + L 26.95 A B
TPO 17.84 B C
APS 17.06 B C
N 11.42 C
R1+R2 C 44.91 A
L 36.05 A B
APS + L 34.78 A B
TPO 25.94 B C
APS 24.68 B C
N 17.17 C
A, B, C and D stand for treatment groups having significantly different
treatment effects. N: Normal, cells cultured in the presence of cytokine and
serum; C: Control, cells grown in cytokine and serum-depleted media; R1:
early apoptotic cell; R2: late apoptotic cell; R1+R2: total apoptotic cell; APS:
Angelica Sinensis Polysaccharide; TPO: Thrombopoietin. L: Ly294002.
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Page 9 of 12samples had significantly higher percentages of cells
expressing Caspase 3 activity, indicative of these treated
cells have undergone apoptosis. APS+Ly294002 treat-
ment significantly decreased the percentage of cells
expressing Caspase 3 activity to 16.02% comparing to
that of Ly294002 alone (23.15%).
Discussion
In our previous study, we showed that DBT extracts can
promote hematopoiesis and thrombopoiesis [4]. Since
APS represents a significant portion of DBT extracts, we
hypothesize that APS may have effects similar to that of
DBT. As we demonstrated in our experiments using
mouse and cell models, APS showed hematopoietic and
thrombopoietic effects similar to those of DBT. These
led us to conclude that APS represents the major active
components in DBT. Two questions have been raised
here. The first one is what the active component of APS
is. APS contains lipid component, it is conceivable that
the plant-derived lipopolysaccharide (LPS) is the major
active component. Since we did detect low level of
endotoxin activity in APS samples using the TAL test,
we cannot exclude the participation of endotoxin-like
activity in our experiments. However, what percentage
of the total activities we detected in this study can be
attributed to this TAL detected activity remains to be
determined.
The second question is what the molecular targets of
APS are. Previous studies suggest that the cellular recog-
nition of LPS is mainly mediated through the interaction
with three proteins, TLR4, CD14, and MD2. LPS binds
to the serum protein LPS-binding protein, and
the resulted complex can be recognized by CD14, a
cell-surface 55-kDa glycoprotein with a glycosyl-phos-
phatidyl-inositol membrane anchor [18]. MD2 is a 20-30
kDa glycoprotein that binds to the extracellular domain
of TLR4 [19], which was identified as an LPS receptor
[20,21]. Several recent studies have further implicated
the three proteins in LPS-induced cellular response. For
example, LPS can induce physical proximity between
CD14 and TLR4 [22]; LPS is in close proximity to TLR4
in the presence of CD14 and MD2 [23] and TLR4 and
MD2 provide greater specificity for ligands and more
efficient responsiveness to LPS [19].
Figure 8 Effects of APS on apoptosis analyzed by Caspase 3
assay. M-07e cells were treated as described above, stained with
Caspase 3-PE (FL-2) and subjected to flow cytometry analysis. (A).
Histogram of Normal, APS-treated, Control, Ly294002-treated, TPO-
treated and APS+Ly294002-treated samples. (B). Quantification and
statistical analyses of treatment effects. Statistical tests were carried
out between the control/treated samples and the corresponding
normal samples respectively. *: p< 0.05; #: p< 0.01 and +: p< 0.001.
Table 4 Effects of various treatments on the apoptosis of
M-07e cells detected by Caspase 3 assay
Treatment
Group
Percentage
of Total Cell
Population (%)
Treatment
Effect Group
L 23.15 A
C 20.38 A B
APS + L 16.02 B C
APS 9.41 C D
N 8.40 D
TPO 6.83 D
A, B, C and D stand for treatment groups having significantly different
treatment effects. N: Normal, cells cultured in the presence of cytokine and
serum; C: Control, cells grown in cytokine and serum-depleted media; APS:
Angelica Sinensis Polysaccharide; TPO: Thrombopoietin. L: Ly294002.
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Page 10 of 12TLR4 is a member of the Toll-like receptors (TLRs)
family, which play a critical role in inducing innate
immune responses in mammals by recognizing con-
served pathogen-associated molecular patterns of bac-
teria [24-26]. So far, 10 human TLRs have been cloned
[27-30]. The TLR agonists include lipopolysaccharide
(LPS) for TLR4, peptidoglycan for TLR2 and TLR6,
double-stranded RNA for TLR3, flagellin for TLR5,
and imidazoquinolines and unmethylated CpG motifs
in bacterial DNA for TLR7 and TLR9, respectively
[31-34]. TLR4 can be activated by nonbacterial ago-
nists such as HSP60, fibronectin, Taxol, respiratory
syncytical virus coat protein, and saturated fatty acids
[35-40].
In terms of the downstream signalling pathway, the
PI3K/AKT Pathways has been suggested as one of the
downstream signalling pathways of TLRs. Wortmannin,
a PI3K inhibitor, inhibits NF B activation and cytokine
production by CpG DNA, a TLR9 agonist and LPS
[41,42]. B lymphocytes deficient in PI3K regulatory units
failed to respond to LPS [43]. The stimulation of TLR2
by Staphylococcus aureus induces the recruitment of
PI3K and the activation of AKT, leading to NF B trans-
activation [44]. These results demonstrate the role of
PI3K in TLR signalling pathways in general. However,
TLR4 does not have a PI3K-binding site. A recent
model suggests that PI3K/AKT is the downstream sig-
nalling component of the MyD88-dependent TLR4 sig-
nalling pathway in particular [45]. Future experiments
are needed to test this MyD88-dependent hypothesis in
details. The results obtained from this study also set the
stage for addressing other important questions, such as
the specificities of APS, if there are any; and whether or
not other chemical components of DBT have similar or
complementary effects.
Conclusions
Here, we showed that APS, the polysaccharide-
enriched extracts from the root of Angelica sinensis
has hematopoietic and thrombopoietic activities in vivo
in a mouse model. In M-07e cells, we showed that
APS can protect cells from undergoing apoptosis and
i t se f f e c t si n v o l v e dt h eP I 3K/AKT Pathways. Taking
together, APS’s hematopoietic and thrombopoietic
effects are likely to result from the activation of the
PI3K/AKT Pathways, the activation of which protects
cells from undergoing apoptosis.
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